Published in Cancer Res on April 15, 2006
Killing cancer cells by targeted drug-carrying phage nanomedicines. BMC Biotechnol (2008) 2.41
High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production. Blood (2012) 1.73
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol (2012) 1.57
Targeted estrogen delivery reverses the metabolic syndrome. Nat Med (2012) 1.51
Protease-activated drug development. Theranostics (2012) 1.36
Immunotoxins for leukemia. Blood (2014) 1.33
Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res (2014) 1.21
Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther (2010) 1.19
Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs (2011) 1.17
Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs (2009) 1.05
Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs (2012) 1.04
Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep (2015) 1.03
High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br J Haematol (2007) 1.03
ADME of antibody-maytansinoid conjugates. AAPS J (2012) 1.03
A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. Proc Natl Acad Sci U S A (2014) 1.00
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs (2011) 0.99
Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther (2012) 0.98
Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J (2015) 0.96
The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin Cancer Res (2013) 0.94
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis (2014) 0.93
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy. Onco Targets Ther (2014) 0.93
Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Nucleic Acids Res (2014) 0.92
Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. PLoS One (2015) 0.89
Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors. PLoS One (2009) 0.89
Antibody drug-conjugates targeting the tumor vasculature: Current and future developments. MAbs (2010) 0.88
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol (2012) 0.88
Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel) (2011) 0.87
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. Biomol Ther (Seoul) (2015) 0.86
Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Ann Transl Med (2014) 0.86
Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists. Bioconjug Chem (2015) 0.85
Monoclonal antibodies in the treatment of pancreatic cancer. Immunotherapy (2009) 0.84
Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. Ther Adv Med Oncol (2014) 0.83
High-content analysis of antibody phage-display library selection outputs identifies tumor selective macropinocytosis-dependent rapidly internalizing antibodies. Mol Cell Proteomics (2014) 0.83
Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine. Cancer Manag Res (2016) 0.83
Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates. Pharm Res (2014) 0.83
Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. AAPS J (2016) 0.82
Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. Future Oncol (2013) 0.82
Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems. Int J Mol Sci (2015) 0.81
The development of potential antibody-based therapies for myeloma. Blood Rev (2014) 0.81
Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. Pharmgenomics Pers Med (2014) 0.80
A mechanistic tumor penetration model to guide antibody drug conjugate design. PLoS One (2015) 0.80
From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer. Gastroenterol Res Pract (2015) 0.80
Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. Cancer Manag Res (2013) 0.79
Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J (2014) 0.79
Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). AAPS J (2016) 0.77
Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection. AAPS J (2015) 0.77
Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy. AAPS J (2016) 0.76
Experimental approaches in the treatment of multiple myeloma. Ther Adv Hematol (2011) 0.76
Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. Oncotarget (2016) 0.76
Structurally Defined αMHC-II Nanobody-Drug Conjugates: A Therapeutic and Imaging System for B-Cell Lymphoma. Angew Chem Int Ed Engl (2016) 0.76
Linkers Having a Crucial Role in Antibody-Drug Conjugates. Int J Mol Sci (2016) 0.75
Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates. Chem Sci (2016) 0.75
Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer. Onco Targets Ther (2016) 0.75
2-(Maleimidomethyl)-1,3-Dioxanes (MD): a Serum-Stable Self-hydrolysable Hydrophilic Alternative to Classical Maleimide Conjugation. Sci Rep (2016) 0.75
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. J Pharmacokinet Pharmacodyn (2016) 0.75
Tracking Antibody Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye Structure and Degree of Labeling on Plasma Clearance. Mol Pharm (2017) 0.75
Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates. ACS Med Chem Lett (2016) 0.75
Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates. Drug Des Devel Ther (2017) 0.75
Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release Properties. Biomacromolecules (2016) 0.75
Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. Adv Ther (2017) 0.75
Antibody-Drug Conjugates for Cancer Therapy. Biomedicines (2016) 0.75
Transport of drugs from blood vessels to tumour tissue. Nat Rev Cancer (2017) 0.75
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res (2009) 2.25
An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res (2003) 2.12
Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl (2014) 2.01
Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol (2011) 1.93
Cytomegalovirus cell death suppressor vMIA blocks Bax- but not Bak-mediated apoptosis by binding and sequestering Bax at mitochondria. Proc Natl Acad Sci U S A (2004) 1.85
In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes. Eur J Immunol (2010) 1.82
A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood (2005) 1.60
Processing of human cytomegalovirus UL37 mutant glycoproteins in the endoplasmic reticulum lumen prior to mitochondrial importation. J Virol (2006) 1.58
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood (2013) 1.56
Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci (2005) 1.55
An anti-apoptotic viral protein that recruits Bax to mitochondria. J Biol Chem (2004) 1.49
Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer (2013) 1.48
Management of advanced primary urethral carcinomas. BJU Int (2014) 1.43
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood (2004) 1.31
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res (2006) 1.30
American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol (2012) 1.29
Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem (2006) 1.29
Cytopathic effects of the cytomegalovirus-encoded apoptosis inhibitory protein vMIA. J Cell Biol (2006) 1.28
Developing drug molecules for therapy with carbon monoxide. Chem Soc Rev (2012) 1.23
Cell killing by antibody-drug conjugates. Cancer Lett (2007) 1.19
A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res (2005) 1.18
Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res (2007) 1.17
Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci (2004) 1.17
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res (2012) 1.16
The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets. EMBO Mol Med (2012) 1.15
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res (2002) 1.15
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res (2011) 1.14
Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res (2010) 1.11
Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina (2006) 1.08
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther (2003) 1.07
Functional outcomes and life satisfaction in long-term survivors of pediatric sarcomas. Arch Phys Med Rehabil (2006) 1.04
Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem (2010) 1.03
Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci (2007) 1.02
Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem (2011) 1.01
Tumor-specific novel taxoid-monoclonal antibody conjugates. J Med Chem (2002) 1.01
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem (2011) 1.01
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. Rapid Commun Mass Spectrom (2005) 0.99
Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. J Comp Eff Res (2013) 0.99
Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg (2013) 0.97
Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther Deliv (2011) 0.91
Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. Pharm Res (2007) 0.91
Study of ocular transport of drugs released from an intravitreal implant using magnetic resonance imaging. Ann Biomed Eng (2005) 0.90
Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Cancer Res (2007) 0.89
Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery. J Med Chem (2004) 0.88
Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer (2010) 0.88
The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res (2005) 0.88
Treatment late effects in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer (2007) 0.88
Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I. Int J Cancer (2009) 0.85
Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant. J Control Release (2005) 0.85
The murine cytomegalovirus cell death suppressor m38.5 binds Bax and blocks Bax-mediated mitochondrial outer membrane permeabilization. Apoptosis (2008) 0.84
Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. Br J Haematol (2008) 0.83
Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. J Med Chem (2012) 0.83
Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models. Clin Cancer Res (2007) 0.82
Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Invest Ophthalmol Vis Sci (2005) 0.79
In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer. Expert Opin Biol Ther (2006) 0.78
Erythrocyte survival is promoted by plasma and suppressed by a Bak-derived BH3 peptide that interacts with membrane-associated Bcl-X(L). Blood (2002) 0.78
Synthesis of potent taxoids for tumor-specific delivery using monoclonal antibodies. Bioorg Med Chem Lett (2004) 0.78
Sustained subconjunctival protein delivery using a thermosetting gel delivery system. J Ocul Pharmacol Ther (2010) 0.77
NICE on rehabilitation. New guidelines on rehabilitation likely to restrict practices and stifle innovation. BMJ (2013) 0.76
Estimation of the differential pressure at renal artery stenoses. Magn Reson Med (2004) 0.75
The effect of the cell death suppressor vMIA on the production of a recombinant protein in the adenovirus-293 expression system. Protein Expr Purif (2008) 0.75
Improving outcomes in the early phases after major trauma. Curr Opin Crit Care (2011) 0.75
Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors. Bioorg Med Chem Lett (2004) 0.75